Skip to content

Effects of omega-7 sea buckthorn oil capsule on mucous membranes of post-menopausal women [omega 7-tyrniöljykapseleiden käyttö vaihdevuosioireiden, emättimen ja muiden limakalvojen kuivuuden ja virtsatieoireiden hoidossa]

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN91680999
Enrollment
100
Registered
2008-08-21
Start date
2008-08-18
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucosa membrane dryness Urological and Genital Diseases Menopausal and other perimenopausal disorders

Interventions

Group one: omega 7 capsules 2 x 2 capsules per day for 4 months Group two: placebo capsules (medium chain triglycerides), 2 x 2 capsules per day for 4 months

Sponsors

Turku University Central Hospital (Finland)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy post-menopausal females aged 55 - 70 years 2. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract 3. Problem of the genital tract mucosa shall not have clear association with severe diseases

Exclusion criteria

Exclusion criteria: 1. Severe diseases and/or receiving systematic medications such as hormone replacement therapy, anti-inflammatory and cholesterol lowering drugs 2. Diabetes 3. Hormonal, renal, haematological, or hepatic dysfunction

Design outcomes

Primary

MeasureTime frame
1. Dryness, itching, pain, burning and/or inflammation in the mucosa of the genital tract at baseline, after one and four months of supplementation 2. Vaginal PH at baseline, after one and four months of supplementation 3. Maturation index of vaginal mucosa at baseline, after one and four months of supplementation

Secondary

MeasureTime frame
1. Plasma total anoxidative capacity at baseline, after one and four months of supplementation 2. Plasma isoprostane level at baseline, after one and four months of supplementation 3. Plasma C-reactive protein level at baseline, after one and four months of supplementation

Countries

Finland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026